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Abstract 
Introduction: Atrial fibrillation (AF) is associated with an increased risk of thromboembolic events. Many 
patients with AF receive chronic anticoagulation, either with vitamin K antagonists (VKAs) or with non-VKA oral 
anticoagulants (NOACs). We sought to analyze variables associated with prescription of NOAC.  
Methods: Patients with AF under anticoagulation treatment were prospectively recruited in this observational 
registry. The sample comprised 1290 patients under chronic anticoagulation for AF, 994 received VKA (77.1%) and 
296 NOAC (22.9%). Univariate and multivariate analyses were performed to identify variables associated with use of 
NOAC.  
Results: Mean age was 73.8 ± 9.4 years, and 42.5% of the patients were women. The CHA2DS2-VASc score was 
0 in 4.9% of the population, 1 in 24.1%, and ≥2 in 71% (median = 4, interquartile range = 2). Variables associated 
with NOAC treatment were major bleeding (odds ratio [OR] = 3.36; confidence interval [CI] 95%: 1.73-6.51; P < 
.001), hemorrhagic stroke (OR = 3.19; CI 95% 1.00-10.15, P = .049), university education (OR = 2.44; CI 95%: 1.55-
3.84; P < .001), high diastolic blood pressure (OR = 1.02; CI 95%: 1.00-1.03; P = .006), and higher glomerular 
filtration rate (OR 1.01, CI 95% 1.00-1.01; P = .01). And variables associated with VKA use were history of cancer 
(OR = 0.46; CI 95%: 0.25-0.85; P = .013) and bradyarrhythmia (OR = 0.40; CI 95% 0.19-0.85; P = .020).  
Conclusion: Medical and social variables were associated with prescription of NOAC. Major bleeding, 
hemorrhagic stroke, university education, and higher glomerular filtration rate were more frequent among patients 
under NOAC. On the contrary, patients with history of cancer or bradyarrhythmias more frequently received VKA.  
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Introduction 
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and the main indication for 
chronic oral anticoagulation worldwide.
1
 Atrial fibrillation is associated with an increased risk of 
thromboembolic events.
2
 Vitamin K antagonists (VKAs) have been the mainstay of oral anticoagulation 
for decades, but they have many limitations including narrow therapeutic window, variability in dose 
response, slow onset and offset of action, and drug and food interactions. Recently, 3 oral anticoagulants 
have proven to be equal or superior to VKA in the prevention of thromboembolic events in patients with 
AF: dabigatran, rivaroxaban, and apixaban (NOAC, standing initially for new oral anticoagulants and 
now for non-VKA oral anticoagulants).
3⇓⇓–6 Current guidelines recommend preferential use of NOAC in 
patients with nonvalvular AF and risk of thromboembolic events.
7
 Nevertheless, the use of NOAC has 
been limited due to both economical and medical reasons. We sought to assess variables associated with 
NOAC versus VKA prescription in the prevention of thromboembolism in AF.  
  
Methods 
Patients 
Fibrilación Auricular: influencia del Nivel y Tipo de Anticoagulación Sobre la Incidencia de Ictus y 
Accidentes hemorrágicos (FANTASIIA) is a multicenter observational study. Cardiologists, general 
practitioners, and internists participated in the study recruiting 20 consecutive patients with nonvalvular 
AF receiving uninterrupted anticoagulant treatment for prevention of stroke for more than 6 months. By 
design, 16 patients had to receive VKA and 4 NOACs. Patients were excluded if they were younger than 
18 years old, had history of heart valve disorder (including prosthesis or moderate/severe valve disease), 
were hospitalized at the moment, or were participating in a clinical trial. Patients unwilling or unable to 
provide written informed consent were also excluded. The study was conducted in Spain. The research 
protocol complied with the Declaration of Helsinki and was approved by the local ethics committee.  
Data Collection 
Demographic data were collected, including labor situation (employed, unemployed, retired, 
disability, and housework), level of education (cannot read or write, primary school, high school, 
vocational training, and college), cardiovascular risk factor, such as high blood pressure, 
hypercholesterolemia, diabetes mellitus, smoking habit, and other comorbidities: chronic obstructive 
pulmonary disease, chronic kidney disease (glomerular filtration rate <60 mL/min), dialysis, liver 
dysfunction (persistent elevation of transaminases 3 times above the upper limit of normality), cancer, 
peripheral artery disease, ictus (ischemic, hemorrhagic, or transient attack), thyroid dysfunction, and 
alcohol consumption. Major bleeding was defined as hemorrhage in a critical anatomical site 
(intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, intramuscular with compartment 
syndrome, or pericardial), bleeding that led to a drop ≥2 g/dL in hemoglobin level or bleeding that 
required transfusion. Cardiac disease such as heart failure, coronary artery disease and other 
cardiomyopathies, previous tachycardia or bradyarrhythmias, ablation, and pacemaker or implantable 
cardioverter defibrillator, were also collected. Data related to AF, including year of diagnosis, symptoms, 
type of AF, and medical treatment were collected. Stroke and hemorrhagic risks were calculated by 
means of the C = Congestive heart failure, H = Hypertension, A = Age ≥ 75 years, D = Diabetes mellitus, 
S = stroke or transient ischemic attack, V = Vascular disease, A = Age 65-74 years Sc = Sex category 
(CHA2DS2-VASc)
8
 and H = Hypertension, A = Abnormal renal/liver function, S = Stroke, B = Bleeding 
history or predisposition, L = Labile INR, E = Elderly >65 y D = Drugs/alcohol (HAS-BLED)
9
 scores. An 
electrocardiogram was performed and blood pressure and heart rate were measured after 5 minutes of 
rest. Weight and height were measured. Laboratory analyses were performed by the laboratory of 
reference of each patient. Medical treatment data were also collected, including type and dose of oral 
anticoagulation, antiarrhythmic drugs, and other cardiovascular medication. In patients treated with VKA, 
the 6 months previous INR controls were collected. A total of 1290 patients were recruited, of those 994 
received VKA (77.1%) and 296 NOAC (22.9%).  
Statistical Analyses 
All continuous variables showed normal distribution and are presented as mean (standard deviation) 
and compared by Student t test. Discrete variables are presented as values (percentages) and compared 
between patients under VKA or NOAC treatment by chi-square test or Fisher exact test, as appropriate. 
Logistic regression analyses were employed for multivariate adjustment. Multivariate models were 
performed including variables with recognized clinical relevance with VKA control and those with a P 
value <.1 in the univariate analysis. Logistic regression was performed by a backward conditional test. 
Results are presented as odds ratio (OR) and 95% confidence interval (CI). A 2-sided P value of <.05 was 
considered to be significant for all analyses. All statistical analyses were performed using SPSS 13.0.  
Results 
Mean age of the study population was 73.8 (9.4) years, and 42% of the patients were women, 81% 
had history of hypertension, 54% dyslipidemia, and 29% diabetes. Only 5% were active smokers. Cardiac 
disease was present in 48%: 376 (28%) patients had history of heart failure, more than half of them with 
preserved ejection fraction, and 18% previous coronary artery disease. In all, 16% had history of 
cerebrovascular disease, 17% of obstructive chronic pulmonary disease, and 19% chronic kidney disease. 
Median (interquartile range) C = Congestive heart failure, H = Hypertension, A = Age ≥ 75 years, D = 
Diabetes mellitus, S = stroke or transient ischemic attack (CHADS2), CHA2DS2-VASc, and HAS-BLED 
were 2 (2), 4 (2), and 2 (2), respectively, and mean (standard deviation) were 2.22 (0.6), 3.64 (0.9), and 
1.93 (0.5), respectively. Of the 1318 patients included, 994 (77%) were under VKA treatment, while 296 
(23%) were under NOAC. In all, 169 (57%) patients were treated with dabigatran, 113 (38%) with 
rivaroxaban, and 14 (5%) with apixaban. Most patients were followed by a cardiologist. Patients under 
VKA treatment were followed by an internist in 7.4% and by primary care in 5.6% and patients treated 
with NOAC in 6.4% and 5.4%, respectively (no differences were observed). However, 93.86% of patients 
treated with VKA and 97.64% with NOAC have been studied by a cardiologist (P = .01). Table 1 shows 
baseline characteristics of the study population stratified by the anticoagulant treatment.  
 
 
Univariate Analysis 
Patients under VKA were older and had higher rates of kidney disease, heart failure, coronary artery 
disease, bradyarrhythmias, and cancer, compared to patients under NOAC treatment. Patients under 
NOAC had higher diastolic blood pressure and glomerular filtration rate, higher frequency of university 
degree, hemorrhagic stroke, and major bleeding.  
Mean and median CHADS2 score was 2.31 (0.6) and 2 (2) in patients treated with VKA and 2.19 (0.6) 
and 2 (2) in patients with NOAC (P = .92), but distribution among categories varied significantly. 
Patients at low risk (CHADS2 = 0-1) were more prone to be treated with NOAC (33.45% were treated 
with NOAC vs 22.86% treated with VKA) while patients at intermediate or high risk (CHADS2 ≥ 2) were 
treated more frequently with VKA (77.14% vs 66.55% treated with NOAC; P < .001, comparing 
treatments in patients with CHADS2 score <2 vs CHADS2 ≥2; Figure 1).  
 
 
 
Figure 1. Patients with CHADS2 score <2 were treated more frequently with non-VKA oral 
anticoagulant (NOAC; 33.4% vs 22.9%) and patients with CHADS2 score ≥2 were treated more 
frequently with vitamin K antagonist (VKA; 77.1% vs 66.6%; chi-square = 12.97; P < .001, 
CHADS2 <2 vs CHADS2 ≥2).  
Mean and median CHA2DS2-VASc score was 3.78 (0.9) and 4 (2) in patients under VKA and 3.6 
(0.9) and 4 (2) in patients under NOAC (P = .104). CHA2DS2-VASc score was 0 in 1.35% of patients 
under NOAC and in 1.21% of patients under VKA, was 1 in 6.08% versus 6.24%. A significant higher 
use of NOAC was found in patients with lower CHA2DS2-VASc score. In all, 28.38% of patients treated 
with NOAC had CHA2DS2-VASc score of 0, 1, or 2, and this proportion was 20.30% in patients treated 
with VKA (P = .003; Figure 2). 
  
 
 
 
Figure 2. Patients with CHA2DS2-VASc score <3 were treated more frequently with NOAC and 
patients with CHA2DS2-VASc score ≥3 were treated more frequently with VKA. Chi-square = 
8.82; P = .001 when comparing CHA2DS2-VASc <3 (28.4% patients were treated with NOAC 
and 20.3% treated with VKA) and CHA2DS2-VASc ≥3 (71.6% and 79.7%, respectively). 
NOCA, non-VKA oral anticoagulant; VKA, vitamin K antagonist.  
Figure 3 shows HAS-BLED score for both anticoagulant treatment strategies. Mean and median HAS-
BLED score was 1.92 (0.5) and 2 (2) in patients under NOAC and 1.98 (0.6) and 2 (2) in patients under 
VKA. Distribution of HAS-BLED score was similar between groups. 
 
 
 
Figure 3. No differences were observed between both the groups. 
  
Multivariate Analysis 
The multivariate analysis (Table 2) showed the following variables associated with NOAC 
prescription: major bleeding (OR = 3.24; CI 95%: 1.68-6.25; P < .001), hemorrhagic stroke (OR = 3.19; 
CI 1.00-10.15; P = .049), university degree (OR = 2.37; CI 95%: 1.52-3.71; P < .001), high diastolic 
blood pressure (OR = 1.02 per mm Hg; CI 95%: 1.01-1.03; P < .001), and higher glomerular filtration 
rate (OR 1.01 per mL/min, CI 95% 1.00-1.01; P = .01), and a trend toward statistical significance was 
observed in long-term persistent AF (OR = 1.80; CI 95%: 0.98-3.30; P = .059).  
 
On the contrary, variables associated with VKA treatment were history of cancer (OR = 0.46; CI 95%: 
0.25-0.85; P = .013) and bradyarrhythmia (OR = 0.39; CI 95% 0.18-0.82; P = .01).  
Discussion 
In the FANTASIIA study, we found the following variables associated with the prescription of NOAC 
over VKA: previous major bleeding, hemorrhagic stroke, having a university degree, higher diastolic 
blood pressure, and higher glomerular filtration rate. Patients with history of cancer and bradyarrhythmia 
were more prone to be treated with VKA.  
Incidence of major bleeding and hemorrhagic stroke seems to be higher in patients under VKA. In the 
HAS-BLED study,
9
 performed with patients under VKA, the major bleeding rate was 1.75% per year. In 
the studies Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY),
3
 Rivaroxaban Once 
Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke 
and Embolism Trial in Atrial Fibrillation (ROCKET-AF),
4
 and Apixaban for Reduction in Stroke and 
Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE),
5
 patients under warfarin presented 
major bleeding rates of 3.36%, 3.4%, and 3.09% per year, respectively, and of hemorrhagic stroke of 
0.74%, 0.70%, and 0.80% per year, respectively. The NOAC showed a significant reduction in 
hemorrhagic stroke (dabigatran 150 mg 0.3%, dabigatran 110 mg 0.23%, rivaroxaban 0.49%, and 
apixaban 0.33%) and similar or inferior major bleeding rates (dabigatran 150 mg 3.11%, dabigatran 110 
mg 2.71%, rivaroxaban 3.6%, and apixaban 2.13%). Therefore, it is expected to find more NOAC 
prescription among patients with history of major bleeding or hemorrhagic stroke.  
The higher glomerular filtration rate found among patients under NOAC is explained by their 
restrictions in case of chronic kidney disease. Depending on the specific drug and the level of renal 
impairment, NOAC may need dose adjustment, special surveillance, or even be contraindicated in case of 
chronic kidney disease. A recent meta-analysis focused on NOAC and kidney disease showed that 
patients with NOAC and kidney disease had higher rates of major bleeding and hemorrhagic stroke 
compared to those without kidney disease and similar to patients treated with warfarin.
10
 
Recently, a Danish registry including more than 18 000 patients treated with VKA or NOAC between 
2011 and 2013 has been published. Patients under NOAC treatment were elder and had higher prevalence 
of heart failure, stroke, myocardial infarction, bleeding, hepatic disease, and alcoholism. The main factor 
associated with VKA treatment was the presence of kidney disease.
11
 In our study, patients under NOAC 
also had higher rates of previous stroke and bleeding, and on the contrary, our analyses revealed that 
patients treated with NOAC were younger and had lower rate of previous heart failure and coronary 
artery disease (Table 1).  
We found a higher prescription of NOAC over VKA in patients with university degrees (12.84% vs 
6.14%, P = .01). Platt and collaborators
12
 described that patients with an active job and those with higher 
education presented worst anticoagulant compliance. This finding has been observed by other groups
13
 
and has been explained as a reflect of mistrust in the medical profession and in the treatment prescribed 
among patients with higher education
14
 and also as a consequence of a reduction in adherence to 
medication and to controls among patients with more workload. Other possible explanation is that 
patients with higher educational degree could be more prone to request NOAC prescription.  
A recently retrospective observational study comparing factors driving anticoagulant selection 
(warfarin, dabigatran, or rivaroxaban) included 70 498 patients, 43 865 treated with warfarin, 21 070 
patients treated with dabigatran, and 5563 patients treated with rivaroxaban.
15
 Patients with higher 
ischemic stroke risk (CHA2DS2-VASc ≥ 2) have 25% less probability to receive dabigatran or 
rivaroxaban, compared with warfarin, and patients at high bleeding risk, defined as a Anticoagulation and 
Risk Factors in Atrial Fibrillation score >5, were less likely to receive an NOAC. Patients were divided 
by level of payment into 3 categories, no/poor coverage (patients pay >80% of costs prescription), fair 
coverage (20%-80%), and good coverage (<20%). Patients with good benefits’ generosity were more 
likely to receive an NOAC. Because in Spain public health coverage is free and universal, the use of 
NOACS has become a financial challenge for the Spanish government and therefore the Ministry of 
Health and The Spanish Medicine Agency published a series of recommendations to regulate NOAC 
prescription.
16
 In this sense, the VKA therapy remains the cornerstone of anticoagulant therapy in patients 
with AF and its use is recommended in patients’ naive to oral anticoagulation. The NOACs are 
recommended in specific clinical scenarios: (1) patients with contraindications to the use of VKA, 
hypersensitivity, or allergy; (2) patients with a history of intracranial hemorrhage; (3) patients with a 
history of stroke and high risk of bleeding (HAS-BLED >3 and leukoaraiosis grade III/IV or multiple 
cortical microbleedings); (4) embolic events in patients with VKA, despite good control of INR; (5) 
VKA-treated patients who have poor control of INR (time in therapeutic range <65% according to 
Rosendaal method
17
 or < 60% as direct calculation, in the previous 6 months); and (6) patients with 
inability to access to the controls of INR. In our study, patients with history of major bleeding and 
intracranial hemorrhage were more frequently treated with NOACS, as recommended. Because of the 
design of the study, we don’t know which patients under treatment of NOCAS were previously treated 
with VKA and if the control of INR was in range or not, but in our experience, the main reason to switch 
from VKA to NOAC is a poor INR control. In our registry,
18
 patients treated with VKA have a mean 
therapeutic time in range (TTR) calculated with Rosendaal method of 60.27% ± 24.48% and 63.77% ± 
23.80% calculated with direct method, and 54% of patients have a poor anticoagulation control (defined 
as TTR <65%; Table 1), thus a large proportion of those patients might have indication of switching to 
NOAC.  
Although several cost-effectiveness studies have demonstrated that NOACs are cost effective in high-
risk patients, both in patients at high embolic or hemorrhagic risk, and in patients with poor control of 
VKA,
19⇓–21 in our study patients with low risk of embolic events (CHADS2 < 2) are more frequently 
treated with NOAC (36.14% vs 26.66% of patients under VKA treatment, P = .002). These differences 
are not observed using CHA2DS2-VASc score, but some investigators recommend the use of CHADS2 
score for most patients, and use the additional variables of CHA2DS2-VASc score in patients with low 
risk in order to decide the indication of anticoagulation.
22
 It is worth remarking that RE-LY, ROCKET-
AF, and ARISTOTLE used CHASD2 score.
3⇓–5 Our data suggest that NOAC are not being prescribed to 
the patients who could benefit most from them.  
The main limitation of our study is the nature of the transversal observational study. Each investigator 
had to recruit the first 16 consecutive patients with VKA and the first 4 with NOAC. This selection 
process prevents the analysis of proportion of anticoagulation type. Patients are representative of a 
Spanish population and results might not be extrapolated to other countries. Another peculiarity of our 
study is that in Spain, the predominant VKA is acenocoumarol as opposed to most Western countries, 
where warfarin is mainly used.  
In conclusion, in the FANTASIIA registry, we found that patients who were prescribed NOAC had 
more frequently history of major bleeding, university education, and higher glomerular filtration rate. On 
the contrary, patients with cancer or bradyarrhythmias received more frequently VKA.  
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